The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen-deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403).
Gwenaelle Gravis
No relevant relationships to disclose
Karim Fizazi
No relevant relationships to disclose
Florence Joly
No relevant relationships to disclose
Stephane Oudard
No relevant relationships to disclose
Frank Priou
No relevant relationships to disclose
Igor Latorzeff
No relevant relationships to disclose
Remy Delva
No relevant relationships to disclose
Benjamin Esterni
No relevant relationships to disclose
Muriel Habibian
No relevant relationships to disclose
Michel Soulie
No relevant relationships to disclose